Mangoceuticals, Inc. Common Stock (MGRX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Mangoceuticals, Inc. Common Stock stock (MGRX) is currently trading at $0.33. Mangoceuticals, Inc. Common Stock PS ratio (Price-to-Sales) is 11.29. WallStSmart rates MGRX as Sell.
- MGRX PE ratio analysis and historical PE chart
- MGRX PS ratio (Price-to-Sales) history and trend
- MGRX intrinsic value — DCF, Graham Number, EPV models
- MGRX stock price prediction 2025 2026 2027 2028 2029 2030
- MGRX fair value vs current price
- MGRX insider transactions and insider buying
- Is MGRX undervalued or overvalued?
- Mangoceuticals, Inc. Common Stock financial analysis — revenue, earnings, cash flow
- MGRX Piotroski F-Score and Altman Z-Score
- MGRX analyst price target and Smart Rating
Mangoceuticals, Inc.
📊 No data available
Try selecting a different time range
Smart Analysis
Mangoceuticals, Inc. Common Stock (MGRX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Mangoceuticals, Inc. Common Stock (MGRX) Key Strengths (1)
Trading below book value, meaning the market prices it less than net assets
Mangoceuticals, Inc. Common Stock (MGRX) Areas to Watch (6)
Company is destroying shareholder value
Losing money on operations
Revenue declining -36.80%, a shrinking business
Very expensive at 11.3x annual revenue
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Mangoceuticals, Inc. Common Stock (MGRX) Detailed Analysis Report
Overall Assessment
This company scores 20/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 1 register as strengths (avg 10.0/10) while 6 fall into concern territory (avg 1.5/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book. Valuation metrics including Price/Book (0.33) suggest the stock is attractively priced.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Revenue Growth. Some valuation metrics including Price/Sales (11.29) suggest expensive pricing. Growth concerns include Revenue Growth at -36.80%, which may limit upside. Profitability pressure is visible in Return on Equity at -136.20%, Operating Margin at -8914.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -136.20% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at -36.80% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
MGRX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
MGRX's Price-to-Sales ratio of 11.29x trades 18% below its historical average of 13.76x (0th percentile). The current valuation is 39% below its historical high of 18.66x set in Mar 2026, and 0% above its historical low of 11.29x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~18.7x as trailing revenue scaled faster than the stock price.
Compare MGRX with Competitors
Top HEALTH INFORMATION SERVICES stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Mangoceuticals, Inc. Common Stock (MGRX) · HEALTHCARE › HEALTH INFORMATION SERVICES
The Big Picture
Mangoceuticals, Inc. Common Stock operates as a stable business with moderate growth and solid fundamentals. Revenue reached 466,910 with 37% decline year-over-year.
Key Findings
Debt-to-equity ratio of 0.01 indicates a conservative balance sheet with 481,281 in cash.
Revenue contracted 37% YoY. Worth determining whether this is cyclical or structural.
Free cash flow is -1M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.33, so expect amplified moves relative to the broader market.
Sector dynamics: monitor HEALTH INFORMATION SERVICES industry trends, competitive moves, and regulatory changes that could impact Mangoceuticals, Inc. Common Stock.
Bottom Line
Mangoceuticals, Inc. Common Stock offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Data sourced from SEC Form 4 filings
Last updated: 10:12:56 AM
About Mangoceuticals, Inc. Common Stock(MGRX)
NASDAQ
HEALTHCARE
HEALTH INFORMATION SERVICES
USA
Mangoceuticals, Inc. focuses to develop, market, and sell various men's wellness products and services through a telemedicine platform. The company is headquartered in Dallas, Texas.